Comment in Response to Proposed Rulemaking: Regulation to Require Drug Pricing Transparency
Letters • 2018On October 18, 2018, the Trump Administration proposed regulations at the Centers for Medicare and Medicaid Services (CMS) to require publication of the list price of any prescription drug or biological product paid by Medicare or Medicaid in direct-to-consumer (DTC) advertising. While TAG applauds the administration's attention to curbing drastic increases in drug prices, list price transparency in DTC advertisements alone will not be a sufficient measure to bring necessary change.
Reality Check: The Price of Bedaquiline
Publication • 2018Bedaquiline is now recommended as a core part of drug-resistant TB treatment, but price is a major concern to ensuring all who need treatment with bedaquiline receive it. The public has made significant investments in the development and introduction of bedaquiline, which should be reflected in the price of bedaquiline. TAG’s “Reality Check” outlines the public’s…
NY State Medicaid Director Announces Potential Path for Volume Based Deal to Expand Hepatitis C Treatment at Lower Price
Statement / Press • 2018On Monday, February 12th, New York State Medicaid Director Jason Helgerson made news by announcing a potential path forward in the State’s response to its major hepatitis C epidemic at the joint Senate/Assembly budget hearing on Health and Medicaid.
Reality Check: The Price of Bedaquiline
PDF • 2018Reality Check: The Price of Bedaquiline
A Pharma View on Delinkage and New Models for Biomedical Innovation: An Interview with Marc Destito from Otsuka Pharmaceutical
TAGline • 2018by Mike Frick and Lindsay McKenna, TB Project Co-Directors, TAG In an interview with TAG’s Tuberculosis (TB) Project, Marc Destito, Senior Director of Public Affairs and Global Alliance Management at Otsuka Pharmaceutical, provides insight into how the development of TB drug delamanid moved the company closer to the principle of delinkage, an approach to biomedical…
TAGline Fall 2018
TAGline • 2018Bringing Down the House on Intellectual Property and Access: As the Trump administration makes noise about the high price of pharmaceuticals while doubling down on its commitment to “protect the engine of American ingenuity,” this issue of TAGline dives deep into the rhetoric and realities of intellectual property (IP) protections and the current wave of political shenanigans on critical drugs, surfacing the fundamental lies and vested interests that deny medication to those in need in the United States and around the world.
Keeping an Eye on Intellectual Property Issues in HIV Cure and Prevention Research
TAGline • 2018By Richard Jefferys, Basic Science, Vaccines, and Cure Project Director, TAG The history of antiretroviral (ARV) drug development offers many examples of compounds that were originally discovered and investigated by publicly funded academic researchers, before being acquired and ushered to market by pharmaceutical companies. Among them is azidothymidine (AZT), the first approved ARV, which was…
Beyond Declarations: Lessons from the UN High-Level Meeting on TB on Building and Transforming Political Will into Real Access to Medicines
TAGline • 2018By Khairunisa Suleiman, Technical Co-Lead, Global TB CAB and Suraj Madoori, U.S. and Global Health Policy Director, TAG On Sept. 26, 2018, the world came together at the United Nations General Assembly in New York for the first-ever High-Level Meeting on Tuberculosis (TB HLM), bringing hope for new political will and resources to jump-start the…
Whose Intellect? Whose Property? A Blueprint for Bringing Down the Pharma IP House of Cards
TAGline • 2018By JD Davids, TAGline Guest Editor and Suraj Madoori, U.S. and Global Health Policy Director, TAG As the Trump administration makes noise about the high price of pharmaceuticals while doubling down on its commitment to “protect the engine of American ingenuity,” this issue of TAGline dives deep into the rhetoric and realities of intellectual property …
Global HCV Elimination Targets and Challenges: An Interview with Andrew Hill
TAGline • 2018By Bryn Gay & Annette Gaudino Are we on track with WHO targets[1,2] to eliminate the hepatitis C virus (HCV) by 2030? Andrew Hill, Senior Research Fellow, Liverpool University unveils powerful research that compares 91 countries’ data on HCV prevalence, diagnosis, treatment, and income level. One central concern is that annually treating an estimated 1.42…